CJC-1295 vs Growth Hormone
Side-by-Side Comparison
| Attribute | Cjc 1295 | Growth Hormone |
|---|---|---|
| Category | Growth Hormone Secretagogue | Hormone |
| Mechanism | CJC-1295 binds to GHRH receptors (GHRHR) on pituitary somatotroph cells, activating intracellular cAMP signaling to stimulate both the transcription of the GH gene and pulsatile release of endogenous... | Growth hormone binds to the GH receptor (GHR), a type I cytokine receptor, activating the JAK2-STAT5 signaling pathway. |
| Evidence Rating | D — Preclinical | A — FDA Approved |
| Clinical Status | Research-only / Not approved for human use | FDA-approved for multiple indications. First approved in 1985 (recombinant form). |
| Safety Profile | Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief; Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) | Common: injection site reactions, edema, joint pain (arthralgia), carpal tunnel syndrome, muscle pain (myalgia); Metabolic: glucose intolerance, insulin resistance (dose-dependent), potential progression to type 2 diabetes |
| Route | Subcutaneous | Subcutaneous |
| Dose Range | No DAC: 100 mcg before bed daily; DAC: 1–2 mg 2–3x weekly | Adults: 0.15–0.3 mg/day SC (GH deficiency); Pediatric: 0.025–0.05 mg/kg/day SC |
| Frequency | Once daily (no DAC) or 2–3 times weekly (with DAC) | Once daily (typically evening) |
| Molecular Weight | No DAC: ~3367.9 g/mol; With DAC: ~3647.3 g/mol | ~22,124 g/mol |
| Half-Life | No DAC (mod GRF 1-29): ~30 min; With DAC: ~8 days | ~20-30 min (endogenous IV); SC injection effective duration ~12-16 hours |
Overview
CJC-1295 and Growth Hormone are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
CJC-1295 — Mechanism & Evidence
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) originally developed by ConjuChem Technologies for HIV-associated lipodystrophy. It exists in two forms: with DAC (Drug Affinity Complex) for extended half-life of 5.8-8.1 days, and without DAC (Mod GRF 1-29) for shorter, pulsatile release with a half-life of approximately 30 minutes. Two 2006 randomized, placebo-controlled, double-blind clinical trials (Teichman et al.) demonstrated dose-dependent GH increases of 2-10 fold and IGF-1 increases of 1.5-3 fold in healthy adults aged 21-61. The No DAC version is generally considered the safer choice due to its physiological pulsatile pattern.
Key claims: Increases growth hormone and IGF-1; Improves body composition; Promotes deep sleep.
Growth Hormone — Mechanism & Evidence
Human growth hormone (hGH, somatotropin) is a 191-amino acid protein produced by the anterior pituitary gland. Recombinant human growth hormone (rhGH, somatropin) is FDA-approved for numerous indications including pediatric and adult growth hormone deficiency, Turner syndrome, short stature from small for gestational age (SGA), Prader-Willi syndrome, chronic kidney disease, idiopathic short stature, and short bowel syndrome (Zorbtive). It is one of the most extensively studied hormones in medicine. Off-label use for anti-aging and performance enhancement is widespread but not approved, and GH is banned by WADA in sport.
Key claims: Treats growth hormone deficiency in children; Treats adult growth hormone deficiency; Anti-aging effects.
Shared Research Applications
These peptides target different research areas. CJC-1295 focuses on Anti-Aging, Body Composition, while Growth Hormone targets GH Deficiency Treatment, Pediatric Growth Disorders, Reference.
Safety Considerations
CJC-1295: Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) Water retention and edema (dose-dependent; elevated GH causes sodium/water retention via kidneys)
Growth Hormone: Common: injection site reactions, edema, joint pain (arthralgia), carpal tunnel syndrome, muscle pain (myalgia) Metabolic: glucose intolerance, insulin resistance (dose-dependent), potential progression to type 2 diabetes Fluid retention: peripheral edema, especially at treatment initiation
Related Products
Related Research News
CJC-1295 with DAC and Ipamorelin: Growth Hormone Research Guide
CJC-1295 with DAC and Ipamorelin represent key compounds in growth hormone research, targeting distinct pathways for GH and IGF-1 signaling. CJC-1295 with DAC acts as a long-acting GHRH analogue with a half-life of 5.8 to 8.1 days, while Ipamorelin functions as a selective growth hormone secretagogue via the ghrelin receptor. Together, they support studies on metabolism, recovery, and body composition.
CJC-1295 + Ipamorelin: Growth Hormone Stack Mechanics
CJC-1295 and Ipamorelin form the most studied growth hormone peptide combination in research. They target separate receptor pathways to boost GH secretion through the somatotropic axis. This stack produces amplified GH pulses, with preclinical data showing 3 to 5 times baseline levels versus 1.5 to 2 times alone.
Ipamorelin: Selective GH Secretagogue for Clean Pulsatile Release
Ipamorelin, a third-generation GHS-R1a agonist (CAS 170851-70-4), stimulates pulsatile growth hormone release without elevating cortisol or prolactin, unlike earlier GHRPs. This selectivity supports precise research into GH axis effects, IGF-1 pathways, body composition, recovery, and sleep. Studies highlight its role in anabolic processes and synergy with CJC-1295 for enhanced GH output.